rs11212617 — ATM

ATM rs11212617 — Where DNA Repair Meets Longevity Pharmacology

The ataxia telangiectasia mutated (ATM) gene encodes one of the master regulators of the cellular DNA damage response — a kinase that springs into action when double-strand DNA breaks are detected, coordinating cell cycle arrest, DNA repair, and, when damage is irreparable, programmed cell death. What makes ATM central to longevity biology is what it does downstream: ATM activates AMPK¹¹ AMPK
AMP-activated protein kinase — the cell's master energy sensor, activated when ADP/AMP ratios rise, and the primary target of metformin's longevity effects, which in turn inhibits mTOR and triggers autophagy. This positions ATM not just as a DNA repair enzyme but as a node connecting genomic stability to the metabolic hallmarks of aging.

The rs11212617 variant sits in an intron within the ATM locus on chromosome 11q22, inside a 340 kb linkage disequilibrium block. The C allele is associated with enhanced metformin response, suggesting it may modify how efficiently ATM activates AMPK under metabolic stress — the same pathway that metformin engages when it inhibits mitochondrial complex I and raises the AMP:ATP ratio.

The Mechanism

Metformin's primary action is inhibition of mitochondrial complex I in the electron transport chain, raising the cellular AMP:ATP ratio and directly activating AMPK. But metformin also appears to engage the ATM-AMPK axis: experimental work using ATM inhibitor KU-55933 in rat hepatoma cells²² experimental work using ATM inhibitor KU-55933 in rat hepatoma cells
Zhou K et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nature Genetics, 2011 showed attenuated AMPK phosphorylation in response to metformin when ATM was blocked. The mechanistic interpretation was complicated by a subsequent finding that KU-55933 also inhibits OCT1 (a metformin transporter), potentially reducing intracellular metformin rather than directly blocking an ATM-AMPK signal. Whether ATM acts directly on AMPK, indirectly through modulating DNA damage-sensing cascades that converge on AMPK, or primarily via effects on metformin transport remains an active question.

What is established is that activated ATM phosphorylates and stabilizes SIRT6, and that ATM activity also restrains mTORC1 via the AMPK-TSC2 pathway after DNA damage. Boosting ATM activity extended lifespan in mouse models of progeria³³ Boosting ATM activity extended lifespan in mouse models of progeria
Qian M et al. Boosting ATM activity alleviates aging and extends lifespan in a mouse model of progeria. eLife, 2018, and ATM-deficient mice show accelerated metabolic dysfunction and premature aging — establishing the gene's role in organismal longevity beyond its classic function in cancer suppression.

The Evidence

The landmark GWAS by Zhou et al. 2011⁴⁴ The landmark GWAS by Zhou et al. 2011
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nature Genetics discovered rs11212617 by scanning 1,024 Scottish type 2 diabetes patients on metformin. In the combined meta-analysis of 3,920 patients, the C allele reached genome-wide significance (P=2.9×10⁻⁹) for metformin treatment success (achieving HbA1c below 7%), with an odds ratio of 1.35 (95% CI 1.22–1.49). Each additional C allele correlated with 0.11% lower HbA1c on metformin treatment (P=6.6×10⁻⁷).

Van Leeuwen et al. 2012⁵⁵ Van Leeuwen et al. 2012
A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia replicated the association across three new cohorts and declared rs11212617 the first robustly replicated common pharmacogenetic variant for metformin (combined five-cohort OR 1.25, P=7.8×10⁻⁶).

However, Florez et al. 2012⁶⁶ Florez et al. 2012
The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. Diabetes Care failed to confirm the association in 2,994 participants treated with metformin for diabetes prevention (HR 1.17, P=0.13). The authors note an important distinction: the DPP enrolled prediabetic individuals while the discovery GWAS enrolled established type 2 diabetics — the biological context of metformin's action may differ substantially between these populations. Multiple other studies in European, South Asian, and East Asian populations have found inconsistent replication, suggesting the association may be population-specific or context-dependent.

In an independent direction, Cuyàs et al. 2019⁷⁷ Cuyàs et al. 2019
METTEN trial — Frontiers in Oncology found that C allele carriers among HER2-positive breast cancer patients had a 7.94-fold higher probability of pathological complete response when treated with neoadjuvant metformin (p=0.011), while no association existed in the control arm — extending the variant's pharmacogenetic relevance to cancer treatment.

The mixed replication record is reflected in the moderate evidence level: the initial GWAS signal is robust within European type 2 diabetes cohorts, but context-dependence, population variation, and an unresolved molecular mechanism prevent elevation to strong.

Practical Actions

The core implication of rs11212617 is pharmacogenetic: C allele carriers — both AC heterozygotes and CC homozygotes — appear to show improved glycemic response to metformin in the context of established type 2 diabetes. For individuals with AA genotype who are prescribed metformin, awareness that this variant may confer reduced metformin efficacy is worth discussing with a clinician, particularly if glycemic targets are not met at standard doses.

Beyond pharmacogenetics, the ATM pathway connects to the same AMPK-mTOR axis that underlies caloric restriction and intermittent fasting biology. The TAME trial (Targeting Aging with Metformin)⁸⁸ TAME trial (Targeting Aging with Metformin) is currently testing whether metformin can extend healthspan in non-diabetic older adults specifically through these longevity pathways. Individual rs11212617 genotype may ultimately predict differential benefit even in that prevention context.

Interactions

rs11212617 operates within the same AMPK-mTOR axis as rs2295080 (MTOR promoter variant). Individuals carrying both the ATM rs11212617 A allele (reduced ATM-AMPK coupling) and MTOR rs2295080 TT genotype (highest mTOR expression) would face a compound disadvantage: reduced capacity to activate AMPK through the ATM route combined with elevated constitutive mTOR activity. This biologically plausible interaction has not been formally tested in a published combined-genotype study. rs2802292 (FOXO3) is also a longevity pathway partner: FOXO3 activity is downstream of AMPK and upstream mTOR signaling, making all three variants part of the same regulatory circuit linking DNA damage response to cellular aging.